{
    "clinical_study": {
        "@rank": "112637", 
        "arm_group": [
            {
                "arm_group_label": "Circadin 2/5/10 mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo arm"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this   study is to establish the efficacy and safety of Circadin in children\n      with neurodevelopmental disorders and to determine the dose, this randomized,\n      placebo-controlled study is planned to evaluate the efficacy of a double-blind, 13 week\n      treatment period with Circadin 2/5mg in improving maintenance of sleep, sleep latency and\n      additional parameters in children with neurodevelopmental disabilities.  The efficacy and\n      safety of Circadin 2/5 mg will continue to be assessed during an open-label extension period\n      of 13 weeks."
        }, 
        "brief_title": "Efficacy and Safety of Circadin\u00ae in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Sleep Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Sleep Disorders", 
                "Dyssomnias", 
                "Parasomnias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Must be children 2 to 17.5 years of age at Visit 2 who comply with taking the study\n             drug.\n\n          2. Must have written informed consent provided by a legal guardian and assent (if\n             needed).\n\n          3. Must have a documented history of ASD according to ICD-10 or DSM-5 or\n             neurodevelopmental disabilities caused by neurogenetic diseases (Smith-Magenis\n             syndrome [SMS], Angelman syndrome, Bourneville's disease [tuberous sclerosis]) as\n             confirmed by case note review showing that diagnosis was reached through assessment\n             by a community paediatrician or paediatric neurologist, who took into account early\n             developmental history and school records.\n\n          4. Must have current sleep problems including: A minimum of 3 months of impaired sleep\n             defined as <6 hours of continuous sleep with more than 0.5 hour sleep latency from\n             light off in 3 out of 5 nights.\n\n          5. Must be on a stable dose of non-excluded medication for 3 months, including\n             anti-epileptics, anti-depressants (SSRIs), stimulants, all mood changing drugs and\n             beta blockers.\n\n          6. The sleep disturbance is not due to the direct physiological effects of the\n             medication (SSRIs, stimulants, etc.).\n\n        At the end of 4 weeks of sleep hygiene training and 2 weeks of placebo run-in, children\n        will be eligible to continue the study if they comply with the following:\n\n          1. Continue to fulfil sleep problem criteria (see Inclusion Criterion 4).\n\n          2. Parents demonstrate compliance in Sleep and Nap Diary completion (5 out of 7 nights).\n\n          3. Continue to fulfil all other eligibility criteria.\n\n        Exclusion Criteria:\n\n          1. Have had treatment with any form of melatonin within 2 weeks prior to Visit 1.\n\n          2. Have a known allergy to melatonin or lactose.\n\n          3. Have a known moderate to severe sleep apnea.\n\n          4. Have untreated medical/ineffectively treated/psychological condition that may be the\n             etiology of sleep disturbances.\n\n          5. Did not respond to previous Circadin therapy based on past medical history records in\n             the last 2 years.\n\n          6. Are taking or have been taking disallowed medication within 2 weeks prior to Visit 1.\n\n          7. Are females of child bearing potential that are not using contraceptives.\n\n          8. Are currently participating in a clinical trial or have participated in a clinical\n             trial involving medicinal product within the last 3 months prior to the study.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01906866", 
            "org_study_id": "NEU_CH_7911"
        }, 
        "intervention": [
            {
                "arm_group_label": "Circadin 2/5/10 mg", 
                "description": "Active arm", 
                "intervention_name": "Circadin 2/5/10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Sleep disturbance", 
            "Circadin", 
            "Prolong realese melatonin", 
            "Autism Spectrum Disorder", 
            "Smith-Magenis Syndrome,", 
            "Angelman Syndrome,", 
            "tuberous sclerosis"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": [
            {
                "contact": {
                    "email": "chris@ehsfamily.com", 
                    "last_name": "Elias Sarkis, MD", 
                    "phone": "352-333-0094"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32607"
                    }, 
                    "name": "Sarkis Clinical Trials"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mperez@crystalbiomedicalresearch.com", 
                    "last_name": "Angel Ernesto Rico, MD", 
                    "phone": "305-828-7900"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami Lakes", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "Crystal BioMedical Research, LLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sergalis@bellsouth.net", 
                    "last_name": "Mary Sergalis"
                }, 
                "contact_backup": {
                    "phone": "561-626-5551"
                }, 
                "facility": {
                    "address": {
                        "city": "West Palm Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Mate Lazlo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "quinlans@kennedykrieger.org", 
                    "last_name": "Robert Findling, MD", 
                    "phone": "443-923-7601"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Kennedy Krieger Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dsteljes@crcnnv.com", 
                    "last_name": "Roshan Raja, MD", 
                    "phone": "702-893-8968"
                }, 
                "facility": {
                    "address": {
                        "city": "Henderson", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89052"
                    }, 
                    "name": "Child Neurology Specialists/ CRCN"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "aking@segalinstitute.com", 
                    "last_name": "Steven Lopez, MD", 
                    "phone": "843-576-6750"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29407"
                    }, 
                    "name": "Carolina Clinical Trials, Inc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "diane.fawkes@vanderbilt.edu", 
                    "last_name": "Beth Malow, MD", 
                    "phone": "615-936-0342"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Vanderbilt University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rahul.shiwach@incr.us", 
                    "last_name": "Rajinder Shiwach, MD", 
                    "phone": "972-283-6286"
                }, 
                "facility": {
                    "address": {
                        "city": "Desoto", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75115"
                    }, 
                    "name": "INSITE Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lmpresearch2@gmail.com", 
                    "last_name": "Samantha Bostrom, MD", 
                    "phone": "386-960-8275"
                }, 
                "facility": {
                    "address": {
                        "city": "Clinton", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "32763"
                    }, 
                    "name": "Ericksen Research & Development"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mallory.wall-tweten@mulitcare.org", 
                    "last_name": "George Makari, MD", 
                    "phone": "253-403-7435"
                }, 
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Multicare Institute for Research and Innovation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Finland", 
                        "country": "Finland"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "France", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "The Netherland", 
                        "country": "Netherlands"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "UK", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Finland", 
                "France", 
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin\u00ae to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities", 
        "overall_contact": {
            "email": "neurim@neurim.com", 
            "last_name": "Neurim Pharmaceutical (1991) Ltd.", 
            "phone": "+972-3-6499340"
        }, 
        "overall_official": [
            {
                "affiliation": "Thoma`s Hospital, Westminster Bridge Rd, London", 
                "last_name": "Paul Gringras, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kennedy Krieger Institute, Baltimore, Maryland, USA", 
                "last_name": "Robert Findling, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Questionnaire", 
            "measure": "The total sleep time will be measured for the Circadin 2/5 mg and placebo by a Sleep and nap diary questionnaire after the 13 week, double-blind treatment period.", 
            "safety_issue": "No", 
            "time_frame": "up to 1.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01906866"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "questionnaire", 
                "measure": "Sleep latency will be measured for the Circadin 2/5 mg and placebo by a Sleep and Nap Diary after 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 years"
            }, 
            {
                "description": "Questionnaire", 
                "measure": "The duration of wake after sleep onset period will be measured for the Circadin 2/5 mg and placebo by a Sleep and Nap Diary after 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 years"
            }, 
            {
                "description": "Questionnaire", 
                "measure": "The number of awakenings during the night will be measured for the Circadin 2/5 mg and placebo by a Sleep and Nap Diary after 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 years"
            }, 
            {
                "description": "Questionnaire", 
                "measure": "The duration of the longest sleep period will be measured for the Circadin 2/5 mg and placebo by a Sleep and Nap Diary after 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 Years"
            }, 
            {
                "description": "Questionnaire", 
                "measure": "The children's social functioning at home, in school, and community settings will be measured for the Circadin 2/5 mg and placebo by the Children Global Assessment Scale (CGAS) Questionnaire after 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 years"
            }, 
            {
                "description": "Questionnaire", 
                "measure": "The children's behavior at home, in school, and community will be measured for the Circadin 2/5 mg and placebo by the Strength of Difficulties Questionnaire (SDQ) Questionnaire filled out by the parents after 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 years"
            }, 
            {
                "measure": "The number of dropouts between Circadin 2/5 mg to that of placebo will be compared during the 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 years"
            }, 
            {
                "description": "The Actigraph will be worn on the wrist  at night and collect the Sleep parameters", 
                "measure": "Sleep parameters (rest/activity cycles) will be measured for the Circadin 2/5 mg and placebo as measured by actigraphy after 13 weeks of double-blind treatment.", 
                "safety_issue": "No", 
                "time_frame": "up to 1.5 years"
            }, 
            {
                "description": "Questionnaire", 
                "measure": "Safety and tolerability throughout the study will be measured for the Circadin 2/5 mg and placebo throughout the study using AE eliciting method Treatment Emergent Signs and Symptoms (TESS)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2.5 years"
            }, 
            {
                "measure": "The following Vital Signs will be measured: blood pressure, pulse, breathing and body temperature. They will be compared between the Circadin and placebo groups.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 2.5 years"
            }
        ], 
        "source": "Neurim Pharmaceuticals Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neurim Pharmaceuticals Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}